Semaglutide

Drug Profile

Semaglutide

Alternative Names: NN-9535; NN-9536; NNC-0113-0217

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Novo Nordisk; Zosano Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 05 Dec 2016 Preregistration for Type-2 diabetes mellitus in European Union (SC)
  • 05 Dec 2016 Preregistration for Type-2 diabetes mellitus in USA (SC)
  • 01 Nov 2016 Novo Nordisk completes a phase II trial in Type-2 diabetes mellitus in USA, Austria, Canada, the Czech Republic, Germany, Malaysia, Russia, Serbia, South Africa and United Kingdom (NCT02461589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top